NCT00345657

Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care

Extended-Release Niacin/Lovastatin Versus Usual Care for Treatment of Dyslipidemia in a Primary Care Setting (EXTEND Study)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (planned)
• Sponsor: In His Image · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.

Detailed description

Both LDL and HDL are important contributors in the pathophysiology of atherosclerosis and coronary artery disease (CAD); however, HDL is often ignored in primary care. The combination of niacin extended-release (ER)/lovastatin in a single tablet formulation (Advicor®) may be the most effective therapeutic option for simultaneously correcting both of these lipoprotein abnormalities to reduce CAD risk. The purpose of this study is to investigate the benefits of combination niacin ER/lovastatin in patients receiving standard care who are not at LDL goal per ATP III guidelines.

Conditions

• Hyperlipidemia
• Mixed Hyperlipidemia
• Dyslipidemia

Interventions

Type	Name	Description
DRUG	Niacin Extended Release/Lovastatin

Timeline

• Start date: 2003-07-01
• Completion: 2004-05-01
• First posted: 2006-06-28
• Last updated: 2006-06-28

Locations

1 site across 1 country: United States